BRIEF published on 07/07/2025 at 15:05, 10 months 3 days ago Applied DNA Sciences se conforme aux normes de cotation du Nasdaq Biotechnologie Sciences Appliquées De L'ADN Conformité Au Nasdaq Technologies De L'ADN LineaRx
BRIEF published on 07/07/2025 at 15:05, 10 months 3 days ago Applied DNA Sciences Complies with Nasdaq Listing Standards Biotechnology Nasdaq Compliance Applied DNA Sciences DNA Technologies LineaRx
PRESS RELEASE published on 07/07/2025 at 15:00, 10 months 3 days ago Applied DNA Regains Compliance with All Nasdaq Continued Listing Requirements Applied DNA Sciences regains compliance with Nasdaq listing rule requiring minimum bid price of $1.00 per share. Company's securities to remain listed on Nasdaq Capital Market Nasdaq Compliance Applied DNA Sciences Nasdaq Capital Market Minimum Bid Price PCR-based DNA Technologies
BRIEF published on 06/17/2025 at 22:15, 10 months 23 days ago Transition de direction chez Applied DNA : le Dr Hayward, PDG, prend sa retraite Biotechnologie Changement De Direction Valeur Actionnariale ADN Appliqué Judy Murrah
BRIEF published on 06/17/2025 at 22:15, 10 months 23 days ago Leadership Transition at Applied DNA as CEO Dr. Hayward Retires Biotechnology Shareholder Value Leadership Change Applied DNA Judy Murrah
PRESS RELEASE published on 06/17/2025 at 22:10, 10 months 23 days ago Applied DNA Announces Retirement of Chairperson and CEO Dr. James A. Hayward Judy Murrah appointed Chairperson and CEO of Applied DNA Sciences, succeeding Dr. James A. Hayward. Experienced executive aims to lead company's innovative DNA technologies CEO Appointment Applied DNA Sciences DNA Technologies Judy Murrah Dr. James A. Hayward
BRIEF published on 05/15/2025 at 22:10, 11 months 26 days ago Applied DNA Sciences enregistre une croissance modeste de ses revenus au deuxième trimestre 2025 Croissance Des Revenus Restructuration Stratégique Résultats Financiers Du Deuxième Trimestre Tendances Biopharmaceutiques Technologie De L'ADN
BRIEF published on 05/15/2025 at 22:10, 11 months 26 days ago Applied DNA Sciences Sees Modest Revenue Growth in Q2 2025 Revenue Growth Strategic Restructuring Q2 Financial Results DNA Technology Biopharma Trends
PRESS RELEASE published on 05/15/2025 at 22:05, 11 months 26 days ago Applied DNA Reports Second Quarter Fiscal 2025 Financial Results Applied DNA Sciences, Inc. (NASDAQ:APDN) reports a 44% Y/Y increase in LineaRx segment revenues contributing to a 6% total revenue growth. Strategic priorities and financial highlights for Q2 2025 disclosed Financial Results Strategic Priorities Applied DNA Sciences LineaRx Segment Therapeutic DNA Production
BRIEF published on 05/14/2025 at 17:35, 11 months 27 days ago Applied DNA Sciences publiera ses résultats financiers du deuxième trimestre et organisera une mise à jour pour les investisseurs Sciences Appliquées De L'ADN Conférence Téléphonique Pour Les Investisseurs Priorités Stratégiques Rediffusion Du Webcast Résultats Financiers Du Deuxième Trimestre 2025
Published on 05/09/2026 at 01:30, 2 days 3 hours ago Star Copper Announces Agreement with Zimtu Capital Corp.
Published on 05/09/2026 at 00:00, 2 days 5 hours ago Onco-Innovations Progresses Toward IND Preparation as Nucro-Technics Commences Bioanalysis for PNKP Inhibitor Technology
Published on 05/10/2026 at 16:05, 13 hours 4 minutes ago RingConn Gen 3 Smart Ring Opens for Pre-Order: Bringing Vascular Insights to Effortless Everyday Wear
Published on 05/10/2026 at 14:00, 15 hours 9 minutes ago MBC GROUP DELIVERS RESILIENT 1Q 2026 PERFORMANCE ANCHORED BY STRONG MBC SHAHID GROWTH
Published on 05/10/2026 at 11:45, 17 hours 24 minutes ago Hisense Kicks Off FIFA World Cup 2026™ Campaign, Bringing Fans Closer Through "Innovating a Brighter Life"
Published on 05/09/2026 at 19:05, 1 day 10 hours ago LONGi EcoLife Series Module Top TaiyangNews Global Ranking, Ushering in the "25%+" Era of Photovoltaic Efficiency
Published on 05/08/2026 at 20:38, 2 days 8 hours ago EQS-Adhoc: thyssenkrupp nucera AG & Co. KGaA: Preliminary Figures for Q2/6M 2025/26; Order Intake Above Expectations and Previous Year ; Sales and Earnings below Market Expectations
Published on 05/07/2026 at 19:15, 3 days 9 hours ago 2026 Annual General Meeting: approval of all resolutions submitted to the Meeting
Published on 05/07/2026 at 19:15, 3 days 9 hours ago Assemblée Générale annuelle 2026 : approbation de l’ensemble des résolutions soumises au vote
Published on 05/07/2026 at 19:06, 3 days 10 hours ago Disclosure of Share Capital and Voting Rights as of April 30, 2026
Published on 05/07/2026 at 19:06, 3 days 10 hours ago Déclaration du nombre d’actions et droits de vote au 30 avril 2026
Published on 05/07/2026 at 19:00, 3 days 10 hours ago ALTAREIT - INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
